Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study

References

• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328–46
   PubMed Web of Science ®Google Scholar
• Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis [Leflunomide Rheumatoid Arthritis Investigators Group]. Arthritis Rheum 2000;43:495–505
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New Engl J Med 2000;343:1586–93
   PubMed Web of Science ®Google Scholar
• Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238–44
   PubMed Web of Science ®Google Scholar
• Lipsky P, Van der Heijde DMFM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. New Engl J Med 2000;343:1594–602
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196–204
   PubMed Web of Science ®Google Scholar
• van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63: 508–16
   PubMed Web of Science ®Google Scholar
• Maetzel A, Bombardier C, Strand V, et al. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. J Rheumatol 1998;25:2331–8
   PubMed Web of Science ®Google Scholar
• Criswell LA, Such CL, Neuhaus JM, et al. Variation among rheumatologists in clinical outcomes and frequency of office visits for rheumatoid arthritis. J Rheumatol 1997;24: 1266–71
   PubMed Web of Science ®Google Scholar
• Galindo-Rodriguez G, Avina-Zubieta JA, Fitzgerald A, et al. Variations and trends in the prescription of initial second line therapy for patients with rheumatoid arthritis. J Rheumatol 1997;24:633–8
   PubMed Web of Science ®Google Scholar
• Suarez-Almazor ME, Soskolne CL, Saunders LD, et al. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness. J Rheumatol 1995;22:836–43
   Google Scholar
• Berthelot JM, Saraux A, Maugars Y, et al. Is combination second-line therapy in rheumatoid arthritis more aggressive than helpful? Revue du Rhumatisme [English Ed.] 1999;66:224–8
   Google Scholar
• McKendry RJ. The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am 1997;234:939–54
   Google Scholar
• George CS, Lichtin AE. Hematologic complications of rheumatic disease therapies. Rheum Dis Clin North Am 1997;23:425–37
   PubMed Web of Science ®Google Scholar
• Balint G, Gergely Jr P. Clinical immunotoxicity of antirheumatic drugs. Inflamm Res 1996;45:S91–S95
   Google Scholar
• Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor α agents in rheumatoid arthritis. Arthritis Rheum 2003;48:313–8
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bathon JM, Martin RW, et al . Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443–50
   Google Scholar
• Byar DP, Simon RM, Friedewald WT, et al. Randomized clinical trials. Perspectives on some recent ideas. New Engl J Med 1976;295:74–80
   PubMed Web of Science ®Google Scholar
• Abel U, Koch A. The role of randomization in clinical studies: myths and beliefs. J Clin Epidemiol 1999;52:487–97
   PubMed Web of Science ®Google Scholar
• Sacks H, Chalmers TC, Smith Jr H. Randomized versus historical controls for clinical trials. Am J Med 1982;72:233–40
   Google Scholar
• Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. I: medical. Stat Med 1989;8:441–54
   Google Scholar
• Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. New Engl J Med 2000;342: 1878–86
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. New Engl J Med 2000;342:1887–92
   Google Scholar
• Steen KS, Lems WF, Aertsen J, et al. Incidence of clinically manifest ulcers and their complications in patients with rheumatoid arthritis. Ann Rheum Dis 2001;60:443–7
   PubMed Web of Science ®Google Scholar
• Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 2000;43: 522–30
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Crowson CS, O’Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999;26: 2529–33
   Google Scholar
• Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999;29:148–58
   Google Scholar
• Gabriel SE, Crowson CS, O’Fallon WM. Comorbidity in arthritis. J Rheumatol 1999;26:2475–9
   Google Scholar
• Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287–93
   PubMed Web of Science ®Google Scholar
• Harrison MJ, Paulus HE, Mena HR, et al. Assessment of predictors of response to DMARD therapies in RA: real world experience in RADIUS [abstract]. Ann Rheum Dis 2005;64:189
   Web of Science ®Google Scholar
• Schiff M, Keystone E, Cush J, et al. Discontinuation of DMARD therapy in patients with rheumatoid arthritis enrolled in RADIUS 1 – rates, reasons, and predictors of early discontinuation [abstract]. Arthritis Rheum 2003; 48:S336
   Google Scholar
• Harrison MJ, Gibofsky A, Keystone E, et al. No change in treatment despite persistence of clinical activity in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2005; 52:S720
   Google Scholar
• Palmer WR, Markenson J, Garjian PA, et al. Update from the RADIUS 1 and 2 observational registries: safety outcomes with DMARD monotherapies and combination therapies [abstract]. Arthritis Rheum 2004;50:S560
   Google Scholar
• Weaver A, Schiff M, Luetkemeyer J, et al. Real-world efficacy outcomes of monotherapies and combination therapies currently used in the treatment of rheumatoid arthritis – results from the RADIUS registries [abstract]. Arthritis Rheum 2004;50: S184–S185
   Google Scholar
• Lautzenheiser RL, Gibofsky A, Shaw RA, et al. Efficacy in a real-world setting: rheumatoid arthritis patient outcomes [abstract]. Arthritis Rheum 2004;50:S699–S700
   Google Scholar
• Weaver A, Lautzenheiser RL, Schiff MH, et al. Real-world effectiveness of select biolgic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin 2006;22:185–98
   PubMed Web of Science ®Google Scholar